Rennie Deflatine Chewable Tablets

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 21/12/17

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 23/3/2015
print

Print ViewKeyword Search SmPC

Bayer Limited

Bayer Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Adalat LA 20 Active Ingredients Nifedipine
Medicine Name Adalat LA 30 Active Ingredients Nifedipine
Medicine Name Adalat LA 60 Active Ingredients Nifedipine
Medicine Name Alka Seltzer Effervescent Tablets Active Ingredients Acetylsalicylic acid (Aspirin), Citric Acid, Sodium Hydrogen Carbonate
Medicine Name Androcur 100 Active Ingredients Cyproterone Acetate
Medicine Name Angeliq 1 mg / 2 mg film-coated tablets Active Ingredients Drospirenone, Estradiol Hemihydrate
Medicine Name Aspirin 300mg Effervescent Tablets Active Ingredients Acetylsalicylic acid (Aspirin)
Medicine Name Avelox 400mg Film-coatedTablets Active Ingredients Moxifloxacin hydrochloride
Medicine Name Avelox 400mg/250ml Solution for Infusion Active Ingredients Moxifloxacin hydrochloride
Medicine Name Bepantiseptic First Aid Cream Active Ingredients Chlorhexidine digluconate, Phenol
Medicine Name Betaferon 250 microgram/ml, powder and solvent for solution for injection Active Ingredients Interferon beta-1b
Medicine Name Canesten 200mg Pessary Active Ingredients Clotrimazole
Medicine Name Canesten 500mg Pessary Active Ingredients Clotrimazole
Medicine Name Canesten Combi Pessary and Cream Active Ingredients Clotrimazole
Medicine Name Canesten Cream Active Ingredients Clotrimazole
Medicine Name Canesten Duopak Active Ingredients Clotrimazole
Medicine Name Canesten HC Cream Active Ingredients Clotrimazole, Hydrocortisone
Medicine Name Canesten Soft Vaginal Capsule Combi Active Ingredients Clotrimazole
Medicine Name Canesten Thrush Cream Active Ingredients Clotrimazole
Medicine Name Ciproxin 250mg Film-coated Tablets Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Ciproxin 500mg Film-coated Tablets Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Ciproxin 750mg Film-coated Tablets Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Ciproxin Solution for Infusion 2mg/ml, 200ml Active Ingredients Ciprofloxacin
Medicine Name Clarityn 10 mg Tablets Active Ingredients Loratadine
Medicine Name Cystopurin 3g Granules for Oral Solution Active Ingredients Potassium Citrate
1 - 0 of 70 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 21 December 2017 PIL

Reasons for updating

  • Change to section 5 - how to store or dispose
  • Change to section 6 - date of revision

Updated on 21 December 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 23 March 2015 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Supply through general sale

Updated on 23 March 2015 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

4.8 Undesirable effects

 

 

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.

 

 

10. DATE OF REVISION OF THE TEXT

 

March 2012March 2015

Updated on 20 March 2015 PIL

Reasons for updating

  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 12 October 2012 PIL

Reasons for updating

  • Change to date of revision
  • Change to name of manufacturer

Updated on 6 July 2012 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to drug interactions
  • Change to further information section

Updated on 17 April 2012 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Section 2:
272mg elemental calcium was added after 680mg for calcium carbonate.

Spelling of simethicone was changed to simeticone.

Section 4.3

'Nephrolithiasis due to calculi containing calcium deposits' replaced nephrocalcinosis.
Severe renal failure (creatinine clearance below 30ml/min) was replaced by 'insufficiency'.

Section 4.4

 

The 2nd paragraph was changed from: "Prolonged use should be avoided. Do not exceed the stated dose and if symptoms persist or only partly disappear, further medical advice should be sought." to "Prolonged use should be avoided. Do not exceed the stated dose and if symptoms persist after 7 days, further medical advice should be sought."

Section 4.5
The following text has been changed from :

·       It has been shown that antacids containing calcium and magnesium may form complexes with certain substances, e.g. antibiotics (tetracyclines, quinolines), and cardiac glycosides, e.g. digoxin, resulting in decreased absorption. This should be borne in mind when concomitant administration is considered.

to :

·       It has been shown that antacids containing calcium and magnesium may form complexes with certain substances, e.g. antibiotics (tetracyclines, quinolines), cardiac glycosides, e.g. digoxin, levothyroxine and eltrombopag, resulting in decreased absorption. This should be borne in mind when concomitant administration is considered.

and "
Thiazide diuretics reduce the urinary excretion of calcium and increase the serum calcium" has been changed to: "Thiazide diuretics reduce the urinary excretion of calcium."

Section 4.6

"Up to now no increased risk of congenital defects.. "  has been changed to "No Thiazide diuretics reduce the urinary excretion of calcium..."

and "see section 4.2" has been added after  "maximum recommended daily dose".

Section 4.8
The immune system disorders section & metabolism and nutrition sections have been updated.The skin and subcutaneous disorders section has been deleted.

Section 5.1 has been updated to:

Pharmacotherapeutic group: Antacids, other combinations; ATC code: A02AX

ATC-Codes: Calcium carbonate A02ACA1, magnesium carbonate A02AA01, silicones A03AX13

 

Rennie Deflatine is a combination of two antacids, calcium carbonate and magnesium carbonate, as well as simeticone, an antifoaming agent.The latter active ingredient causes gas bubbles to coalesce and disperse, thus liberating any trapped gas.

The mode of action of calcium carbonate & magnesium carbonate is local, based on the neutralisation of gastric acid, and is not dependent on systemic absorption. Calcium carbonate has a rapid, long-lasting and powerful neutralising action. This effect is increased by the addition of magnesium carbonate which also has a strong neutralising action. In vitro, the total neutralising capacity of the product is 16 mEq H+ (titration to endpoint pH 2.5)

Section 5.2 has been updated to:

In the stomach, calcium carbonate and magnesium carbonate react with the acid in the gastric juice, forming water and soluble mineral salts.

 

CaCO3 + 2HCl => CaCl2 + H2O + CO2

MgCO3 + 2HCl =>MgCl2 + H2O + CO2

 

Calcium and magnesium can be absorbed from these soluble salts. However, the degree of absorption is dependent on the subject and the dose. Less than 10% calcium and 15-20% magnesium is absorbed.

 

The small quantities of calcium and magnesium absorbed are usually excreted rapidly via the kidneys in healthy individuals. In case of impaired renal function, plasma concentrations of calcium and magnesium may be increased.



Updated on 17 June 2010 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 29 March 2010 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Section 4.2 has been changed to reduce the max daily dose to 11 tablets. A warning has also been added for the use of Rennie Deflatine in persons below 18.

 

 

Section 4.3 has been altered to say

Rennie Deflatine should not be administered in the following cases:

 

·       Hypersensitivity to any of the ingredients of the product

 

·       Hypercalcemia, hypercalciuria and/or conditions resulting in hypercalcaemia e.g. sarcoidosis

 

·       Nephrocalcinosis

 

·       Severe renal failure (creatinine clearance below 30 ml/min)

 

·       Hypophosphatemia”

 

 

Section 4.4 has been updated to say

“Rennie Deflatine should be used with caution in the following case:

 

·       Caution should generally be exercised in the case of patients with impaired renal function. If Rennie Deflatine is to be used in these patients, plasma calcium, phosphate and magnesium levels should be regularly monitored.

 

Prolonged use should be avoided. Do not exceed the stated dose and if symptoms persist, consult your doctor.

 

As with other antacids, Rennie Deflatine tablets may mask a malignancy in the stomach.

Long term use at high doses can result in undesirable effects such as hypercalcemia, hypermagnesemia and milk-alkali syndrome, especially in patients with renal insufficiency. The product should not be taken with large amounts of milk or dairy products.

Prolonged use possibly enhances the risk for the development of kidney stones.

 

Patients with rare hereditary problems of fructose intolerance should not take this medicine.

 

Magnesium salts may cause central nervous system depression in the presence of renal insufficiency.”

 

 

Section 4.5 now reads

Changes in gastric acidity, e.g. during treatment with antacids, may impair the rate and degree of absorption of other drugs, if taken concomitantly.

 

·       It has been shown that antacids containing calcium and magnesium may form complexes with certain substances, e.g. antibiotics (tetracyclines, quinolines), and cardiac glycosides, e.g. digoxin, resulting in decreased absorption. This should be borne in mind when concomitant administration is considered.

 

·       Thiazide diuretics reduce the urinary excretion of calcium and increase the serum calcium. Due to an increased risk of hypercalcemia, serum calcium should be regularly monitored during concomitant use of thiazide diuretics.

 

·       Calcium and magnesium salts can also impede the absorption of phosphates, fluorides, and iron containing products.

 

Therefore it is preferable to administer the antacid separately from other drugs, allowing a 1-2 hours interval.”

 

 

Section 4.6 has been updated to say:

Up to now, no increased risk of congenital defects has been observed after the use of calcium carbonate and magnesium carbonate during pregnancy. In case of high or prolonged doses or renal insufficiency, the risk for hypercalcaemia and/or hypermagnaesia can not be completely excluded.

Rennie Deflatine tablets can be used during pregnancy if taken as instructed but prolonged intake of high dosages should be avoided. Rennie Deflatine tablets can be used during lactation if taken as instructed.

During pregnancy and lactation, it has to be taken into account that Rennie Deflatine tablets provide a substantial amount of calcium in addition to dietary calcium intake. For this reason, pregnant women should strictly limit their use of Rennie Deflatine chewable tablets to the maximum recommended daily dose and avoid concomitant, excessive intake of milk and dairy products. This warning is to prevent calcium overload which might result in milk alkali syndrome.”

 

Section 4.8 now reads:

The listed adverse drug reactions are based on spontaneous reports, thus an organization according to CIOMS III categories of frequency is not possible.

 

Immune System Disorders

Hypersensitivity reactions including anaphylaxis have been reported.

 

Metabolism and Nutrition Disorders

Especially in patients with impaired renal function, prolonged use of high doses can result in hypercalcemia and alkalosis which may give rise to gastric symptoms and muscular weakness (see below).

 

Gastrointestinal Disorders

Nausea, vomiting, stomach discomfort and diarrhea may occur.

 

Musculoskeletal and Connective Tissue Disorders

Muscular weakness may occur.

 

Skin and Subcutaneous Disorders

Rash, urticaria, and angioedema in context of hypersensitive reactions.

 

Undesirable effects only occurring in the context of milk-alkali syndrome (see 4.9):

Gastrointestinal Disorders

Ageusia may occur in the context of milk-alkali syndrome.

 

General Disorders and Administration Site Conditions

Calcinosis and asthenia may occur in the context of milk-alkali syndrome.

 

Nervous System Disorders

Headache may occur in the context of milk-alkali syndrome.

 

Renal and Urinary Disorders

Azotemia may occur in the context of milk-alkali syndrome.”

 

 

Section 4.9 now reads:

“Especially in patients with impaired renal function, prolonged use of high doses of calcium carbonate and magnesium carbonate can result in renal insufficiency, hypermagnesemia, hypercalcemia and alkalosis which may give rise to gastrointestinal symptoms (nausea, vomiting, constipation) and muscular weakness. In these cases, the intake of the product should be stopped and adequate fluid intake encouraged. In severe cases of overdosage (e.g. milk-alkali syndrome), a health care professional must be consulted because other measures of rehydration (e.g. infusions) might be necessary.”

 

 

Section 10 has been updated to February 2010.

Updated on 4 March 2010 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 4 November 2009 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

In section 6.3 (Shelf Life), the shelf life has been changed from 5 to 3 years.

In section 6.4 (Special precautions for storage), Storage conditions have been changes from no special requirements to store below 25ºc. 

Updated on 9 July 2009 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
  • Change to section 2 - Qualitative and quantitative composition

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Section 1: Name updated to:

 

Rennie Deflatine Chewable Tablets

Calcium carbonate 680mg

Magnesium Carbonate 80mg

Simeticone 25mg

Section 2:

'Excipients : Contains Sorbitol (E420) 430mg' has been added.  

Updated on 20 March 2009 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Supply through general sale